【佳学基因检测】癌症基因组测序：未来的挑战

品牌基因检测联系方式—客观性

开题评估《肿瘤突变基因检测与个性化治疗方案的制定》《Bioessays》在 2007 Aug;29(8):783-94发表了一篇题目为《癌症基因组测序：未来的挑战》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Henry H Q Heng 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

0

肿瘤靶向治疗基因检测临床应用结果

癌症基因组图谱 (TCGA) 项目的一个主要挑战是解决癌症的高水平遗传和表观遗传异质性。对于大多数实体瘤，进化模式是随机的，最终产物是不可预测的，这与在许多血液癌症中经典描述的相对可预测的逐步模式形成对比。此外，在癌症中产生异常水平的系统异质性的主要因素是基因组异常，而不是基因突变。癌症的这些特征可以显着降低测序方法的影响，因为只有当突变基因是癌症的主要原因时，直接对其进行测序才是合理的。许多生物因素（遗传和表观遗传变异、代谢过程）和环境影响会增加癌症形成的可能性，具体取决于给定的情况。这些因素之间的共同联系是随机基因组变异，这些变异为生物系统多个层面的癌症进化过程提供了驱动力。这一分析表明，癌症是一种概率疾病，对 TCGA 项目最具挑战性的问题，以及抗击癌症的总体战略的制定，都处于概念层面。

肿瘤发生与复发转移国际数据库描述：

A major challenge for The Cancer Genome Atlas (TCGA) Project is solving the high level of genetic and epigenetic heterogeneity of cancer. For the majority of solid tumors, evolution patterns are stochastic and the end products are unpredictable, in contrast to the relatively predictable stepwise patterns classically described in many hematological cancers. Further, it is genome aberrations, rather than gene mutations, that are the dominant factor in generating abnormal levels of system heterogeneity in cancers. These features of cancer could significantly reduce the impact of the sequencing approach, as it is only when mutated genes are the main cause of cancer that directly sequencing them is justified. Many biological factors (genetic and epigenetic variations, metabolic processes) and environmental influences can increase the probability of cancer formation, depending on the given circumstances. The common link between these factors is the stochastic genome variations that provide the driving force behind the cancer evolutionary process within multiple levels of a biological system. This analysis suggests that cancer is a disease of probability and the most-challenging issue to the TCGA project, as well as the development of general strategies for fighting cancer, lie at the conceptual level.